引用次数
引用: 1,206
H-指数: 18
I10-指数 : 23
出版物: 112
68P Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer
K. O'Byrne , S.-L. Ryan , S. Heavey , K. Umezawa
Journal of Thoracic Oncology 11 ( 4) S84
2016
8 The effects of PI3K/Akt/mTOR pathway inhibitors on a panel of NSCLC cell lines
S. Heavey , M. Barr , K. O'Byrne , K. Gately
Lung Cancer 75
2012
7 NFkB–IκBα interaction: a mechanism of resistance to cisplatin in NSCLC
S. Heavey , M. Barr , C. Edwards , K. O'Byrne
Lung Cancer 75
2012
1 Elucidating the role of inflammatory mediators in cisplatin resistant NSCLC
A.M. Baird , P. Godwin , S. Heavey , K. Umezawa
Lung Cancer 79
2013
9 Elucidating the role of the NFkB pathway in cisplatin resistant NSCLC
P. Godwin , S. Heavey , A.M. Baird , M.P. Barr
Lung Cancer 79
2013
8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC
S. Heavey , M.A. Davies , K.J. O'Byrne , K. Gately
Lung Cancer 79
2013
4 DHMEQ, an NFkB inhibitor, inhibits cell proliferation and induces apoptosis in cisplatin resistant NSCLC
S. Heavey , A.M. Baird , P. Godwin , M.P. Barr
Lung Cancer 79
2013
89 Targeting nuclear factor-kappa B in malignant pleural mesothelioma
K. Gately , E. Jennions , P. Godwin , M.P. Barr
Lung Cancer 79
2013
1 Targeting NF-κB regulated pathways to overcome cisplatin resistance in non-small cell lung cancer
A.-M. Baird , P. Godwin , S. Heavey , K. Umezawa
Lung Cancer 83
1
2014
9 Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort
S. Heavey , M.P. Barr , B. Hennessy , S. Toomey
Lung Cancer 83
2014
10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980
S. Heavey , M.P. Barr , S. Finn , S. Cuffe
Lung Cancer 83
2014
5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines
S. Heavey , P. Dowling , M. Barr , S. Cuffe
Lung Cancer 87
2015
4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer
A.-M. Baird , P. Godwin , S. Heavey , M. Barr
Lung Cancer 87
2015
Activated cMyc/PIM kinase promotes resistance to PI3K/mTOR inhibition in NSCLC
G. Moore , S. Heavey , K. O’Byrne , S. Cuffe
Lung Cancer 115
1
2018
Distinct immunohistochemical findings for common biomarkers in malignant and adjacent benign prostate: A study on needle biopsy microarrays derived from mpMRI-characterized tissue
V. Stavrinides , J. Olivier , J. Kay , A. Freeman
European Urology Supplements 17 ( 2)
2018
Co-Targeting The PI3K-MTOR & MEK Pathways in NSCLC
S. Heavey , M. Barr , A. Ahmad , A. Davies
Annals of Oncology 23
2012
Targeting NFKB in Cisplatin Resistant NSCLC
K.A. Gately , S. Heavey , P. Godwin , M. Barr
Annals of Oncology 23
2012
Activation of Akt by Hypoxia Predicts Poor Outcome in Malignant Pleural Mesothelioma (MPM)
K.A. Gately , D. Stewart , S. Heavey , A. Davies
Annals of Oncology 23
2012
Nuclear Factor-Kappa B as a Molecular Target in Malignant Pleural Mesothelioma
K.A. Gately , E. Jennions , P. Godwin , M. Barr
Annals of Oncology 23
2012
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
P. Godwin , A. M. Baird , S. Heavey , M. P. Barr
Frontiers in Oncology 3 120 -120
143
2013
Kathy Gately Martin Barr Hayley Whitaker Hayley Pye Shonit Punwani Edward W Johnston D J Hawkes Benjamin S Simpson Professor Caroline M Moore Daniel C. Alexander Eleftheria (Laura) Panagiotaki Ashwin narasimha SRIDHAR Mark Emberton Lina Maria Carmona Echeverria Professor Hashim U Ahmed Vasilis Stavrinides Roger M. Bourne Bernard Siow Thomy Mertzanidou David Atkinson